<DOC>
	<DOCNO>NCT01721434</DOCNO>
	<brief_summary>Levosimendan relatively new drug improve cardiac contractility patient heart failure . Its main mechanism action enhance bind calcium myocardial contractile protein . Recent data lab show levosimendan improves contractility human diaphragm vitro ( muscle fiber COPD patient diaphragm ) vivo ( healthy subject ) . Accordingly , levosimendan may appear value treatment disorder associate impaired respiratory muscle function , mechanically ventilated patients.We hypothesize levosimendan could improve respiratory muscle function mechanically ventilate patient commence CPAP trial .</brief_summary>
	<brief_title>Effects Levosimendan Diaphragm Function Mechanically Ventilated Patients</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>mechanical ventilation &gt; 3 day inform consent able sustain CPAP trial 30 minute PaO2/FiO2 ratio &gt; 200 mmHg ventilatory setting : positive end expiratory pressure &lt; = 10 cmH2O , pressure support &lt; = 10 cmH2O preexistent muscle disease ( congenital acquire ) diseases/disorders know associated myopathy include autoimmune disease preexistent cardiac disease ( base history , electrocardiography transthoracic echocardiography ) upper airway/esophageal pathology ( i.e . recent surgery , esophageal varix , diaphragmatic hernia ) phrenic nerve lesion pregnancy , breast feeding severe renal failure ( serum creatinine &gt; 150 umol/L ) severe hepatic failure recent ( within 5 day ) nasal bleed systolic blood pressure &lt; 120 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>levosimendan</keyword>
	<keyword>diaphragm function</keyword>
	<keyword>mechanically ventilated patient</keyword>
	<keyword>neuro-mechanical efficiency</keyword>
</DOC>